Pleading Standards in Mass Tort Cases After Iqbal - Dinsmore ...
Pleading Standards in Mass Tort Cases After Iqbal - Dinsmore ...
Pleading Standards in Mass Tort Cases After Iqbal - Dinsmore ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Product Liability<br />
<strong>Mass</strong> <strong>Tort</strong>s and Class Actions<br />
<strong>in</strong> a Post-<strong>Iqbal</strong> World<br />
S<strong>in</strong>ce <strong>Iqbal</strong> came down, it has been cited<br />
thousands of times and has been the subject<br />
of commentary both <strong>in</strong> pr<strong>in</strong>t and<br />
onl<strong>in</strong>e. Because a plead<strong>in</strong>g’s adequacy is<br />
measured by the federal rules regardless<br />
of where a case was orig<strong>in</strong>ally filed, <strong>Iqbal</strong>’s<br />
significance will be felt <strong>in</strong> cases orig<strong>in</strong>ally<br />
filed <strong>in</strong> federal court and <strong>in</strong> cases removed<br />
from state court. See Hanna v. Plumer, 380<br />
U.S. 460 (1965); Hayduk v. Lanna, 775 F.2d<br />
441, 443 (1st Cir. 1985). This section will<br />
discuss cases apply<strong>in</strong>g <strong>Iqbal</strong> <strong>in</strong> the mass<br />
torts and class action context.<br />
A number of courts have already relied<br />
on <strong>Iqbal</strong> to support dismiss<strong>in</strong>g compla<strong>in</strong>ts<br />
under Rule 12(b)(6), and understand<strong>in</strong>g<br />
the sort of allegations now deemed <strong>in</strong>sufficient<br />
will help <strong>in</strong> assess<strong>in</strong>g whether to seek<br />
dismissal <strong>in</strong> a particular case. For example,<br />
<strong>in</strong> S<strong>in</strong>altra<strong>in</strong>al v. Coca-Cola Co., 578 F.3d<br />
1252, 1257 (11th Cir. 2009), the Eleventh<br />
Circuit reversed a denied dismissal motion<br />
<strong>in</strong> a case <strong>in</strong> which the defendants, employers<br />
who allegedly collaborated with Colombian<br />
paramilitary forces to murder and<br />
torture the pla<strong>in</strong>tiffs, trade union leaders.<br />
The pla<strong>in</strong>tiffs’ allegations that the paramilitary<br />
forces had acted as arms of the state<br />
had been essential to their claim. In hold<strong>in</strong>g<br />
that these allegations had been <strong>in</strong>sufficiently<br />
substantiated <strong>in</strong> the <strong>in</strong>itial plead<strong>in</strong>g,<br />
the Court stated:<br />
[P]la<strong>in</strong>tiffs allege the paramilitary are<br />
“permitted to exist” and are “assisted”<br />
by the Colombian government. Additionally,<br />
the pla<strong>in</strong>tiffs allege “[i]t is universally<br />
acknowledged that the regular<br />
military and the civil government authorities<br />
<strong>in</strong> Colombia tolerate the paramilitaries,<br />
allow them to operate, and<br />
often cooperate, protect and/or work<br />
<strong>in</strong> concert with them.” These pla<strong>in</strong>tiffs<br />
also contend the paramilitaries are state<br />
actors who had a symbiotic relationship<br />
with the Colombian military and<br />
thus operated under color of law. The<br />
pla<strong>in</strong>tiffs’ conclusory allegation that the<br />
paramilitary security forces acted under<br />
color of law is not entitled to be assumed<br />
true and is <strong>in</strong>sufficient to allege statesponsored<br />
action. See <strong>Iqbal</strong>, 129 S. Ct. at<br />
1951. Colombia’s mere “registration and<br />
toleration of private security forces does<br />
not transform those forces’ acts <strong>in</strong>to state<br />
70 n For The Defense n December 2009<br />
acts.” Allegations the Colombian government<br />
tolerated and permitted the paramilitary<br />
forces to exist are <strong>in</strong>sufficient<br />
to plead the paramilitary forces were<br />
state actors. The pla<strong>in</strong>tiffs make the naked<br />
allegation the paramilitaries were<br />
<strong>in</strong> a symbiotic relationship with the Colombian<br />
government and thus were state<br />
actors. Nevertheless, <strong>in</strong> test<strong>in</strong>g the sufficiency<br />
of the pla<strong>in</strong>tiff’s allegations, we<br />
do not credit such conclusory allegations<br />
as true. See <strong>Iqbal</strong>, 129 S. Ct. at 1951. We<br />
demand allegations of a symbiotic relationship<br />
that “<strong>in</strong>volves the torture or kill<strong>in</strong>g<br />
alleged <strong>in</strong> the compla<strong>in</strong>t to satisfy the<br />
requirement of state action.” There is no<br />
suggestion the Colombian government<br />
was <strong>in</strong>volved <strong>in</strong>, much less aware of, the<br />
murder and torture alleged <strong>in</strong> the compla<strong>in</strong>ts.<br />
The pla<strong>in</strong>tiffs’’ “formulaic recitation,”<br />
Twombly, 550 U.S. at 555, 127 S.<br />
Ct. at 1965, that the paramilitary forces<br />
were <strong>in</strong> a symbiotic relationship and<br />
were assisted by the Colombian government,<br />
absent any factual allegations to<br />
support this legal conclusion, is <strong>in</strong>sufficient<br />
to state to support an allegation of<br />
state action that is plausible on its face.<br />
See <strong>Iqbal</strong>, 129 S. Ct. at 1950.<br />
S<strong>in</strong>altra<strong>in</strong>al, 578 F.3d at 1266 (some <strong>in</strong>ternal<br />
citations omitted).<br />
In Pa. Emples. Benefit Trust Fund v.<br />
Astrazeneca Pharms. LP, 2009 U.S. Dist.<br />
LEXIS 76555 (M.D. Fla. 2009), the pla<strong>in</strong>tiff<br />
had provided health <strong>in</strong>surance and prescription<br />
drug coverage to employees of the<br />
Commonwealth of Pennsylvania. Alleg<strong>in</strong>g<br />
that the defendant, a pharmaceutical<br />
manufacturer, improperly promoted and<br />
marketed Seroquel, the pla<strong>in</strong>tiff sought to<br />
recoup funds it had expended on behalf<br />
of members who had been prescribed the<br />
medic<strong>in</strong>e. In address<strong>in</strong>g the sufficiency<br />
of the compla<strong>in</strong>t’s allegations of breach of<br />
warranty, the Court stated:<br />
As to any direct communication of<br />
express warranties from Defendant to<br />
Pla<strong>in</strong>tiff, Defendant po<strong>in</strong>ts out that the<br />
compla<strong>in</strong>t is devoid of facts support<strong>in</strong>g<br />
even an <strong>in</strong>ference that the terms of any<br />
alleged warranties were received by Pla<strong>in</strong>tiff<br />
directly from the company. Pla<strong>in</strong>tiff<br />
counters by referr<strong>in</strong>g to four paragraphs<br />
<strong>in</strong> the compla<strong>in</strong>t conta<strong>in</strong><strong>in</strong>g allegations<br />
that AstraZeneca conveyed its alleged<br />
warranties “[t]hrough its label<strong>in</strong>g, as<br />
well as its sales and market<strong>in</strong>g practices<br />
and documents given or shown to physicians<br />
treat<strong>in</strong>g PEBTF participants and/<br />
or the PEBTF itself….” Notably, however,<br />
the allegations of direct communication<br />
are entirely unsupported by<br />
facts conta<strong>in</strong>ed elsewhere <strong>in</strong> the compla<strong>in</strong>t.<br />
As the Supreme Court of the<br />
United States recently clarified, a federal<br />
compla<strong>in</strong>t does not “suffice if it tenders<br />
‘naked asser tion[s]’ devoid of ‘further<br />
factual enhancement.’” <strong>Iqbal</strong>, 129 S. Ct.<br />
at 1949.Furthermore, even Pla<strong>in</strong>tiff’s<br />
“naked assertions” of direct contact with<br />
Defendant are vaguely stated; Pla<strong>in</strong>tiff<br />
<strong>in</strong>dicates that AstraZeneca’s market<strong>in</strong>g<br />
materials and Seroquel label<strong>in</strong>g were<br />
“given or shown to physicians treat<strong>in</strong>g<br />
PEBTF participants and/or PEBTF<br />
itself.” Such equivocal allegations suggest<br />
that PEBTF itself is unsure whether<br />
it received any direct market<strong>in</strong>g <strong>in</strong>formation<br />
from AstraZeneca regard<strong>in</strong>g uses<br />
of Seroquel that were unapproved by the<br />
FDA. Indeed, a close read<strong>in</strong>g of the compla<strong>in</strong>t<br />
strongly suggests that AstraZeneca’s<br />
alleged warranties reached PEBTF<br />
only by way of a treat<strong>in</strong>g physician’s prescription<br />
pad, if at all. See Doc. 3 at 31<br />
(“Pennsylvania physicians who treat,<br />
and prescribe medications for, PEBTF<br />
participants necessarily act as the <strong>in</strong>termediary<br />
between Defendant and the<br />
Pla<strong>in</strong>tiff.”); id. at 6 (“The PEBTF and its<br />
PBM [“phar macy benefit manager”] rely<br />
on persons caus<strong>in</strong>g claims to be submitted<br />
for payment by the Pla<strong>in</strong>tiff to recognize<br />
and honor the permissible scope<br />
of reimbursement and to obey the govern<strong>in</strong>g<br />
law and regulations <strong>in</strong> activities<br />
that cause such claims.”); id. at 32<br />
(“Defendant breached the express warranties<br />
it made to the PEBTF, through<br />
physicians participat<strong>in</strong>g <strong>in</strong> PEBTF….”)<br />
(emphasis added). In sum, the Court<br />
need not credit Pla<strong>in</strong>tiff’s bald allegations<br />
of any direct communication of<br />
express warranties from Defendant for<br />
purposes of the motion to dismiss.<br />
Pa. Emples. Benefit Trust Fund, 2009 U.S.<br />
Dist. LEXIS 76555, at *8–10. Note the difference<br />
between this hold<strong>in</strong>g and that of<br />
the magistrate judge’s pre-<strong>Iqbal</strong> decision <strong>in</strong><br />
Peters v. Amoco.<br />
Of course, not everyth<strong>in</strong>g has come<br />
up roses for defendants <strong>in</strong> the post-<strong>Iqbal</strong>